SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0000950170-24-049269
Filing Date
2024-04-26
Accepted
2024-04-26 16:57:39
Documents
13
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A fnch-20231231.htm   iXBRL 10-K/A 512027
2 EX-31.1 fnch-ex31_1.htm EX-31.1 8928
3 EX-31.2 fnch-ex31_2.htm EX-31.2 9142
  Complete submission text file 0000950170-24-049269.txt   780280

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fnch-20231231.xsd EX-101.SCH 51719
16 EXTRACTED XBRL INSTANCE DOCUMENT fnch-20231231_htm.xml XML 10918
Mailing Address 75 STATE STREET SUITE 100 BOSTON MA 02109
Business Address 75 STATE STREET SUITE 100 BOSTON MA 02109 617-229-6499
Finch Therapeutics Group, Inc. (Filer) CIK: 0001733257 (see all company filings)

IRS No.: 823433558 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-40227 | Film No.: 24884856
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)